COPD

COPD patients with unnoticed OSA are at a greater risk of hospital readmission and even all-cause mortality.

Al Rizzo, MD, of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Breaking down the details of the E3 trial, and what more needs to be found in the follow-up.

New ACC findings show smokers given nicotine or non-nicotine e-cigarettes better in 12-week cessation than those just given counseling.

A study of 416 hospitalized patients indicates 19.7% suffered cardiac injury, which was also associated with increased ventilation and mortality.

New expanded analysis from the IMPACT trial shows FF/UMEC/VI's benefit versus dual inhaler therapies.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Technology, data, and community partnerships can help improve the overall health of patients with chronic health conditions.

Roy Schoenberg, MD, MPH, discusses the populations that can most benefit from using telehealth tools and Medicare reimbursement obstacles.

The new low nicotine products contain 95% less nicotine than the top 100 cigarette brands in the US, according to 22nd Century Group.

A new guidance breaks ground as the first of its kind to assist physicians in screening for, and treating, vaping-associated respiratory disease syndrome.

New follow-up data shows older patients with COPD characterized by high blood eosinophil counts may benefit from the biologic.

New VDAART follow-up findings show at-risk children are not safer from asthma or recurrent wheeze when their mother takes prenatal vitamin D.

New research into the role of legislation on vaping use shows certain laws may be more effective than others.

New cohort data shows significantly worsened respiratory symptoms among patients with comorbid cough and COPD.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New data shows the market-controlling e-cigarette product nearly doubled its rate of young adult users in just 1 year.

New findings show patients with HDHPs are more likely to skip inhaler therapy due to costs, and are therefore more frequently hospitalized.

A long-term comparison trial with smokers motivated to quit show the combination of alternative nicotine products could slightly and safely improve cessation.

A comparison of virtual training to in-person education showed the former was noninferior to the latter among patients with asthma or COPD.

The US Food and Drug Administration has announced a comprehensive ban on flavored, pod-based e-cigarette cartridges earlier this week.

A re-prioritization of disease monitoring and screening could help physicians better understand how one of the greatest killers in the US could be combated.

An assessment of metoprolol in older patients with COPD had to be discontinued after treated patients reported a greater rate of hospitalization due to exacerbations.

A new cohort analysis shows hospitalized smokers are not at complication risk due to the perioperative therapy.